Date: 2014-02-09
Type of information: Private placement
Company: Atara Biotherapeutics (USA - CA)
Investors:
Amount:
Funding type: private placement
Planned used:
Others: * On February 18, 2015, Atara Biotherapeutics, a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, announced the closing of its public offering of 4,147,358 shares of its common stock at a public offering price of $18.00 per share, which included 509,025 shares sold pursuant to the partial exercise by the underwriters of their option to purchase additional shares. * On February 12, 2015, Atara Biotherapeutics announced the pricing of its underwritten public offering of 3,638,333 shares of its common stock at a public offering price of $18.00 per share. In addition, Atara Bio has granted the underwriters a 30-day option to purchase up to an additional 545,749 shares of common stock at the public offering price. The offering is expected to close on February 18, 2015, subject to customary closing conditions. * On February 9, 2015, Atara Biotherapeutics announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. In addition, Atara Bio expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares. All of the shares in the offering will be sold by Atara Bio. Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the proposed offering. Jefferies LLC is acting as co-manager. A registration statement related to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The offering is being made only by means of a written prospectus forming part of the effective registration statement.
Therapeutic area: Cancer - Oncology - Kidney diseases - Renal diseases
